Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Transl Psychiatry. 2022 Aug 11;12(1):330. doi: 10.1038/s41398-022-02103-9.
Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psilocybin induces long-lasting effects on behavior, likely due to its profound ability to alter consciousness and augment neural connectivity and plasticity. Impaired synaptic plasticity in obesity contributes to 'addictive-like' behaviors, including heightened motivation for palatable food, and excessive food seeking and consumption. Here, we evaluate the effects of psilocybin on feeding behavior, energy metabolism, and as a weight-lowering agent in mice. We demonstrate that a single dose of psilocybin substantially alters the prefrontal cortex transcriptome but has no acute or long-lasting effects on food intake or body weight in diet-induced obese mice or in genetic mouse models of obesity. Similarly, sub-chronic microdosing of psilocybin has no metabolic effects in obese mice and psilocybin does not augment glucagon-like peptide-1 (GLP-1) induced weight loss or enhance diet-induced weight loss. A single high dose of psilocybin reduces sucrose preference but fails to counter binge-like eating behavior. Although these preclinical data discourage clinical investigation, there may be nuances in the mode of action of psychedelic drugs that are difficult to capture in rodent models, and thus require human evaluation to uncover.
裸盖菇素和其他血清素能致幻剂重新成为神经精神疾病的治疗方法,包括成瘾。裸盖菇素会对行为产生持久的影响,这可能是因为它具有深刻地改变意识、增强神经连接和可塑性的能力。肥胖症中突触可塑性的损伤导致“类似成瘾”的行为,包括对美味食物的更高动机、过度的食物寻求和消费。在这里,我们评估了裸盖菇素对摄食行为、能量代谢以及作为减肥药在小鼠中的作用。我们表明,单次剂量的裸盖菇素会显著改变前额叶皮层的转录组,但在饮食诱导肥胖的小鼠或肥胖的遗传小鼠模型中,对食物摄入或体重没有急性或长期影响。同样,亚慢性微剂量的裸盖菇素对肥胖小鼠没有代谢作用,裸盖菇素也不会增强胰高血糖素样肽-1 (GLP-1) 诱导的体重减轻或增强饮食诱导的体重减轻。单次高剂量的裸盖菇素会降低蔗糖偏好,但不能阻止暴食行为。尽管这些临床前数据不鼓励进行临床研究,但致幻药物的作用模式可能存在细微差别,难以在啮齿动物模型中捕捉到,因此需要进行人体评估才能揭示。